Lisa P. Rumin
Subscribe to Lisa P. Rumin's Posts
Lisa P. Rumin focuses her practice on antitrust, regulatory and litigation matters. She assists clients across a variety of industries and has represented numerous clients in the healthcare, pharmaceutical, and biotechnology industries. Lisa advises clients on mergers and acquisitions, including obtaining clearance from the Federal Trade Commission (FTC) and Department of Justice (DOJ), as well as counsels clients on issues regarding antitrust compliance, pricing, and distribution. Read Lisa Rumin's full bio here.
By Stefan M. Meisner and Lisa P. Rumin on Jun 17, 2020
Posted In Cartel Enforcement, DOJ Developments, FTC Developments
The COVID-19 pandemic has brought not only a healthcare crisis, but also one of the worst economic downturns in history. As businesses emerge from this crisis, there may be increased risk that employees may cross the line and engage in anticompetitive conduct. Therefore, it is critical that companies and individuals prepare now to ensure that...
By Joel R. Grosberg and Lisa P. Rumin on May 28, 2020
Posted In FTC Developments, Mergers & Acquisitions
Since September 2019, the Federal Trade Commission has challenged noncompete provisions in at least three transactions. These challenges demonstrate that the FTC will challenge noncompete provisions even when it concludes that the underlying transaction raises no substantive antitrust issues and when the provision relates to minority investments. Noncompete provisions help protect a buyer’s significant investment...
By Stefan M. Meisner, Nicole Castle, Lisa P. Rumin and Stephen Wu on May 21, 2020
Posted In Private Litigation
The US Court of Appeals for the Third Circuit recently concluded in In re Lamictal Direct Purchaser Antitrust Litigation that a district court’s reliance on average prices to determine class-wide impact was insufficient. Instead, courts must conduct a rigorous analysis of the facts, evidence and expert testimony at the class certification stage of litigation. Access Full Article
By Lisa P. Rumin, Jon B. Dubrow and Will Diaz on Feb 4, 2020
Posted In Consumer Protection/Privacy, FTC Developments, Healthcare Antitrust
Today the Federal Trade Commission (FTC) and the Food and Drug Administration (FDA) released joint guidance concerning competition for biologics, including biosimilars. The joint guidance seeks to enhance competition for biologics and reduce manufacturers’ use of false or misleading statements or promotional communications concerning the efficacy or safety of biosimilars and other biologics. This guidance...